Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

WCLC 2024

WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in patients with ROS1+ non-small cell lung cancer

WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in...

WCLC 2024: Results from CARMEN-LC03 phase 3 study of tusamitamab ravtansine vs. docetaxel in previously treated advanced non-squamous NSCLC

WCLC 2024: Results from CARMEN-LC03 phase 3 study of tusamitamab ravtansine vs. docetaxel in previously treated...

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met protein-overexpressing EGFR WT nonsquamous NSCLC

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met...

WCLC 2024: Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS compared to placebo

WCLC 2024: Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS...

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do not respond well to EGFR-TKIs therapy

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do...

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib analysis of beamion LUNG-1

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib...

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients with HER2-mutant NSCLC

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients...

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients with NSCLC with EGFR PACC mutations

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients...

WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer

WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in...

WCLC 2024: Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data releases at IASLC 2024 World Conference on Lung Cancer

WCLC 2024: Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data...

WCLC 2024: Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer

WCLC 2024: Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage...

WCLC 2024: IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer biomarker testing

WCLC 2024: IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer...

WCLC 2024: Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors

WCLC 2024: Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors

WCLC 2024: Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive advanced NSCLC in HARMONi-2 study

WCLC 2024: Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive...

WCLC 2024: Normalised membrane ratio of TROP2 by quantitative continuous scoring predictive of clinical outcomes in TROPION-Lung 01

WCLC 2024: Normalised membrane ratio of TROP2 by quantitative continuous scoring predictive of clinical outcomes...

WCLC 2024: PanCan nodule management protocol more effective than LungRADSv1.1 method

WCLC 2024: PanCan nodule management protocol more effective than LungRADSv1.1 method

WCLC 2024: Perioperative nivolumab may provide meaningful improvement in event-free survival compared to only neoadjuvant nivolumab plus chemotherapy for resectable NSCLC

WCLC 2024: Perioperative nivolumab may provide meaningful improvement in event-free survival compared to only...

WCLC 2024: NeoCOAST-2 Data shows combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC -- Data builds on AEGEAN study research

WCLC 2024: NeoCOAST-2 Data shows combination of Durvalumab with novel agents increases pathological responses in...

More from ecancer